Pneumococcal vaccination at 65 years and vaccination coverage in at-risk adults: A retrospective population-based study in France
Age (> 50 years) is a risk factor for pneumococcal disease, but is not an indication for vaccination in France, by contrast to influenza. In 2018, the pneumococcal vaccine coverage rate (VCR) was 4.5% in adults at-risk, in contrast to the influenza VCR, which was 43.6%. We aimed to assess pneumoc...
Gespeichert in:
| Veröffentlicht in: | PloS one Jg. 20; H. 8; S. e0329703 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
United States
Public Library of Science
11.08.2025
Public Library of Science (PLoS) |
| Schlagworte: | |
| ISSN: | 1932-6203, 1932-6203 |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | Age (> 50 years) is a risk factor for pneumococcal disease, but is not an indication for vaccination in France, by contrast to influenza. In 2018, the pneumococcal vaccine coverage rate (VCR) was 4.5% in adults at-risk, in contrast to the influenza VCR, which was 43.6%. We aimed to assess pneumococcal and influenza VCR in 2020 in the entire French population and factors associated with a higher VCR (including the age of 65 years).
We retrospectively included all adults covered by the National Health Service in 2020 and identified patients at-risk using validated algorithms. We assessed VCRs by analysing pneumococcal vaccines reimbursed between 2009 and 2020 (13-valent pneumococcal conjugate vaccine [PCV13] and 23-valent polysaccharide vaccine [PPSV23]), and influenza vaccines reimbursed between September 2020 and March 2021.
In 2020, we identified 7,336,769 adults at risk (median age: 67.0 years): 84.2% had comorbidities and 24.5% were immunocompromised. The overall pneumococcal VCR (PCV13 + PPSV23) was 9.9% and the seasonal influenza VCR was 51.1%. The variable associated with the highest odds of VCR was an "age ≥65 years" for influenza (odds ratio [OR] 4.14), but not for pneumococcal vaccination (OR 1.02). In patients with comorbidities, pneumococcal VCR did not significantly increase between those aged 18-65 years and those aged > 65 years (7.2% to 9.4%), and even decreased from 20% to 17.9% in patients with immunodeficiencies. In contrast, influenza VCR increased significantly from 35.5% to 67.9% (OR 3.55) in patients with comorbidities, and from 27.3% to 71.2% (OR 5.57) in those with immunodeficiencies.
In France, pneumococcal VCR did not increase above 65 years of age (OR 1.02), by contrast to influenza VCR (OR 4.14) that increased significantly, suggesting that an age-based recommendation for pneumococcal vaccination will probably benefit to VCR in at-risk, elderly population. |
|---|---|
| AbstractList | Objectives
Age (> 50 years) is a risk factor for pneumococcal disease, but is not an indication for vaccination in France, by contrast to influenza. In 2018, the pneumococcal vaccine coverage rate (VCR) was 4.5% in adults at-risk, in contrast to the influenza VCR, which was 43.6%. We aimed to assess pneumococcal and influenza VCR in 2020 in the entire French population and factors associated with a higher VCR (including the age of 65 years).
Methods
We retrospectively included all adults covered by the National Health Service in 2020 and identified patients at-risk using validated algorithms. We assessed VCRs by analysing pneumococcal vaccines reimbursed between 2009 and 2020 (13-valent pneumococcal conjugate vaccine [PCV13] and 23-valent polysaccharide vaccine [PPSV23]), and influenza vaccines reimbursed between September 2020 and March 2021.
Results
In 2020, we identified 7,336,769 adults at risk (median age: 67.0 years): 84.2% had comorbidities and 24.5% were immunocompromised. The overall pneumococcal VCR (PCV13 + PPSV23) was 9.9% and the seasonal influenza VCR was 51.1%. The variable associated with the highest odds of VCR was an “age ≥65 years” for influenza (odds ratio [OR] 4.14), but not for pneumococcal vaccination (OR 1.02). In patients with comorbidities, pneumococcal VCR did not significantly increase between those aged 18–65 years and those aged > 65 years (7.2% to 9.4%), and even decreased from 20% to 17.9% in patients with immunodeficiencies. In contrast, influenza VCR increased significantly from 35.5% to 67.9% (OR 3.55) in patients with comorbidities, and from 27.3% to 71.2% (OR 5.57) in those with immunodeficiencies.
Conclusion
In France, pneumococcal VCR did not increase above 65 years of age (OR 1.02), by contrast to influenza VCR (OR 4.14) that increased significantly, suggesting that an age-based recommendation for pneumococcal vaccination will probably benefit to VCR in at-risk, elderly population. ObjectivesAge (> 50 years) is a risk factor for pneumococcal disease, but is not an indication for vaccination in France, by contrast to influenza. In 2018, the pneumococcal vaccine coverage rate (VCR) was 4.5% in adults at-risk, in contrast to the influenza VCR, which was 43.6%. We aimed to assess pneumococcal and influenza VCR in 2020 in the entire French population and factors associated with a higher VCR (including the age of 65 years).MethodsWe retrospectively included all adults covered by the National Health Service in 2020 and identified patients at-risk using validated algorithms. We assessed VCRs by analysing pneumococcal vaccines reimbursed between 2009 and 2020 (13-valent pneumococcal conjugate vaccine [PCV13] and 23-valent polysaccharide vaccine [PPSV23]), and influenza vaccines reimbursed between September 2020 and March 2021.ResultsIn 2020, we identified 7,336,769 adults at risk (median age: 67.0 years): 84.2% had comorbidities and 24.5% were immunocompromised. The overall pneumococcal VCR (PCV13 + PPSV23) was 9.9% and the seasonal influenza VCR was 51.1%. The variable associated with the highest odds of VCR was an “age ≥65 years” for influenza (odds ratio [OR] 4.14), but not for pneumococcal vaccination (OR 1.02). In patients with comorbidities, pneumococcal VCR did not significantly increase between those aged 18–65 years and those aged > 65 years (7.2% to 9.4%), and even decreased from 20% to 17.9% in patients with immunodeficiencies. In contrast, influenza VCR increased significantly from 35.5% to 67.9% (OR 3.55) in patients with comorbidities, and from 27.3% to 71.2% (OR 5.57) in those with immunodeficiencies.ConclusionIn France, pneumococcal VCR did not increase above 65 years of age (OR 1.02), by contrast to influenza VCR (OR 4.14) that increased significantly, suggesting that an age-based recommendation for pneumococcal vaccination will probably benefit to VCR in at-risk, elderly population. Age (> 50 years) is a risk factor for pneumococcal disease, but is not an indication for vaccination in France, by contrast to influenza. In 2018, the pneumococcal vaccine coverage rate (VCR) was 4.5% in adults at-risk, in contrast to the influenza VCR, which was 43.6%. We aimed to assess pneumococcal and influenza VCR in 2020 in the entire French population and factors associated with a higher VCR (including the age of 65 years). We retrospectively included all adults covered by the National Health Service in 2020 and identified patients at-risk using validated algorithms. We assessed VCRs by analysing pneumococcal vaccines reimbursed between 2009 and 2020 (13-valent pneumococcal conjugate vaccine [PCV13] and 23-valent polysaccharide vaccine [PPSV23]), and influenza vaccines reimbursed between September 2020 and March 2021. In 2020, we identified 7,336,769 adults at risk (median age: 67.0 years): 84.2% had comorbidities and 24.5% were immunocompromised. The overall pneumococcal VCR (PCV13 + PPSV23) was 9.9% and the seasonal influenza VCR was 51.1%. The variable associated with the highest odds of VCR was an "age [greater than or equal to]65 years" for influenza (odds ratio [OR] 4.14), but not for pneumococcal vaccination (OR 1.02). In patients with comorbidities, pneumococcal VCR did not significantly increase between those aged 18-65 years and those aged > 65 years (7.2% to 9.4%), and even decreased from 20% to 17.9% in patients with immunodeficiencies. In contrast, influenza VCR increased significantly from 35.5% to 67.9% (OR 3.55) in patients with comorbidities, and from 27.3% to 71.2% (OR 5.57) in those with immunodeficiencies. In France, pneumococcal VCR did not increase above 65 years of age (OR 1.02), by contrast to influenza VCR (OR 4.14) that increased significantly, suggesting that an age-based recommendation for pneumococcal vaccination will probably benefit to VCR in at-risk, elderly population. Age (> 50 years) is a risk factor for pneumococcal disease, but is not an indication for vaccination in France, by contrast to influenza. In 2018, the pneumococcal vaccine coverage rate (VCR) was 4.5% in adults at-risk, in contrast to the influenza VCR, which was 43.6%. We aimed to assess pneumococcal and influenza VCR in 2020 in the entire French population and factors associated with a higher VCR (including the age of 65 years). We retrospectively included all adults covered by the National Health Service in 2020 and identified patients at-risk using validated algorithms. We assessed VCRs by analysing pneumococcal vaccines reimbursed between 2009 and 2020 (13-valent pneumococcal conjugate vaccine [PCV13] and 23-valent polysaccharide vaccine [PPSV23]), and influenza vaccines reimbursed between September 2020 and March 2021. In 2020, we identified 7,336,769 adults at risk (median age: 67.0 years): 84.2% had comorbidities and 24.5% were immunocompromised. The overall pneumococcal VCR (PCV13 + PPSV23) was 9.9% and the seasonal influenza VCR was 51.1%. The variable associated with the highest odds of VCR was an "age ≥65 years" for influenza (odds ratio [OR] 4.14), but not for pneumococcal vaccination (OR 1.02). In patients with comorbidities, pneumococcal VCR did not significantly increase between those aged 18-65 years and those aged > 65 years (7.2% to 9.4%), and even decreased from 20% to 17.9% in patients with immunodeficiencies. In contrast, influenza VCR increased significantly from 35.5% to 67.9% (OR 3.55) in patients with comorbidities, and from 27.3% to 71.2% (OR 5.57) in those with immunodeficiencies. In France, pneumococcal VCR did not increase above 65 years of age (OR 1.02), by contrast to influenza VCR (OR 4.14) that increased significantly, suggesting that an age-based recommendation for pneumococcal vaccination will probably benefit to VCR in at-risk, elderly population. Objectives: Age (> 50 years) is a risk factor for pneumococcal disease, but is not an indication for vaccination in France, by contrast to influenza. In 2018, the pneumococcal vaccine coverage rate (VCR) was 4.5% in adults at-risk, in contrast to the influenza VCR, which was 43.6%. We aimed to assess pneumococcal and influenza VCR in 2020 in the entire French population and factors associated with a higher VCR (including the age of 65 years).Methods: We retrospectively included all adults covered by the National Health Service in 2020 and identified patients at-risk using validated algorithms. We assessed VCRs by analysing pneumococcal vaccines reimbursed between 2009 and 2020 (13-valent pneumococcal conjugate vaccine [PCV13] and 23-valent polysaccharide vaccine [PPSV23]), and influenza vaccines reimbursed between September 2020 and March 2021.Results: In 2020, we identified 7,336,769 adults at risk (median age: 67.0 years): 84.2% had comorbidities and 24.5% were immunocompromised. The overall pneumococcal VCR (PCV13 + PPSV23) was 9.9% and the seasonal influenza VCR was 51.1%. The variable associated with the highest odds of VCR was an “age ≥65 years” for influenza (odds ratio [OR] 4.14), but not for pneumococcal vaccination (OR 1.02). In patients with comorbidities, pneumococcal VCR did not significantly increase between those aged 18–65 years and those aged > 65 years (7.2% to 9.4%), and even decreased from 20% to 17.9% in patients with immunodeficiencies. In contrast, influenza VCR increased significantly from 35.5% to 67.9% (OR 3.55) in patients with comorbidities, and from 27.3% to 71.2% (OR 5.57) in those with immunodeficiencies.Conclusion: In France, pneumococcal VCR did not increase above 65 years of age (OR 1.02), by contrast to influenza VCR (OR 4.14) that increased significantly, suggesting that an age-based recommendation for pneumococcal vaccination will probably benefit to VCR in at-risk, elderly population. Objectives Age (> 50 years) is a risk factor for pneumococcal disease, but is not an indication for vaccination in France, by contrast to influenza. In 2018, the pneumococcal vaccine coverage rate (VCR) was 4.5% in adults at-risk, in contrast to the influenza VCR, which was 43.6%. We aimed to assess pneumococcal and influenza VCR in 2020 in the entire French population and factors associated with a higher VCR (including the age of 65 years). Methods We retrospectively included all adults covered by the National Health Service in 2020 and identified patients at-risk using validated algorithms. We assessed VCRs by analysing pneumococcal vaccines reimbursed between 2009 and 2020 (13-valent pneumococcal conjugate vaccine [PCV13] and 23-valent polysaccharide vaccine [PPSV23]), and influenza vaccines reimbursed between September 2020 and March 2021. Results In 2020, we identified 7,336,769 adults at risk (median age: 67.0 years): 84.2% had comorbidities and 24.5% were immunocompromised. The overall pneumococcal VCR (PCV13 + PPSV23) was 9.9% and the seasonal influenza VCR was 51.1%. The variable associated with the highest odds of VCR was an "age [greater than or equal to]65 years" for influenza (odds ratio [OR] 4.14), but not for pneumococcal vaccination (OR 1.02). In patients with comorbidities, pneumococcal VCR did not significantly increase between those aged 18-65 years and those aged > 65 years (7.2% to 9.4%), and even decreased from 20% to 17.9% in patients with immunodeficiencies. In contrast, influenza VCR increased significantly from 35.5% to 67.9% (OR 3.55) in patients with comorbidities, and from 27.3% to 71.2% (OR 5.57) in those with immunodeficiencies. Conclusion In France, pneumococcal VCR did not increase above 65 years of age (OR 1.02), by contrast to influenza VCR (OR 4.14) that increased significantly, suggesting that an age-based recommendation for pneumococcal vaccination will probably benefit to VCR in at-risk, elderly population. Age (> 50 years) is a risk factor for pneumococcal disease, but is not an indication for vaccination in France, by contrast to influenza. In 2018, the pneumococcal vaccine coverage rate (VCR) was 4.5% in adults at-risk, in contrast to the influenza VCR, which was 43.6%. We aimed to assess pneumococcal and influenza VCR in 2020 in the entire French population and factors associated with a higher VCR (including the age of 65 years).OBJECTIVESAge (> 50 years) is a risk factor for pneumococcal disease, but is not an indication for vaccination in France, by contrast to influenza. In 2018, the pneumococcal vaccine coverage rate (VCR) was 4.5% in adults at-risk, in contrast to the influenza VCR, which was 43.6%. We aimed to assess pneumococcal and influenza VCR in 2020 in the entire French population and factors associated with a higher VCR (including the age of 65 years).We retrospectively included all adults covered by the National Health Service in 2020 and identified patients at-risk using validated algorithms. We assessed VCRs by analysing pneumococcal vaccines reimbursed between 2009 and 2020 (13-valent pneumococcal conjugate vaccine [PCV13] and 23-valent polysaccharide vaccine [PPSV23]), and influenza vaccines reimbursed between September 2020 and March 2021.METHODSWe retrospectively included all adults covered by the National Health Service in 2020 and identified patients at-risk using validated algorithms. We assessed VCRs by analysing pneumococcal vaccines reimbursed between 2009 and 2020 (13-valent pneumococcal conjugate vaccine [PCV13] and 23-valent polysaccharide vaccine [PPSV23]), and influenza vaccines reimbursed between September 2020 and March 2021.In 2020, we identified 7,336,769 adults at risk (median age: 67.0 years): 84.2% had comorbidities and 24.5% were immunocompromised. The overall pneumococcal VCR (PCV13 + PPSV23) was 9.9% and the seasonal influenza VCR was 51.1%. The variable associated with the highest odds of VCR was an "age ≥65 years" for influenza (odds ratio [OR] 4.14), but not for pneumococcal vaccination (OR 1.02). In patients with comorbidities, pneumococcal VCR did not significantly increase between those aged 18-65 years and those aged > 65 years (7.2% to 9.4%), and even decreased from 20% to 17.9% in patients with immunodeficiencies. In contrast, influenza VCR increased significantly from 35.5% to 67.9% (OR 3.55) in patients with comorbidities, and from 27.3% to 71.2% (OR 5.57) in those with immunodeficiencies.RESULTSIn 2020, we identified 7,336,769 adults at risk (median age: 67.0 years): 84.2% had comorbidities and 24.5% were immunocompromised. The overall pneumococcal VCR (PCV13 + PPSV23) was 9.9% and the seasonal influenza VCR was 51.1%. The variable associated with the highest odds of VCR was an "age ≥65 years" for influenza (odds ratio [OR] 4.14), but not for pneumococcal vaccination (OR 1.02). In patients with comorbidities, pneumococcal VCR did not significantly increase between those aged 18-65 years and those aged > 65 years (7.2% to 9.4%), and even decreased from 20% to 17.9% in patients with immunodeficiencies. In contrast, influenza VCR increased significantly from 35.5% to 67.9% (OR 3.55) in patients with comorbidities, and from 27.3% to 71.2% (OR 5.57) in those with immunodeficiencies.In France, pneumococcal VCR did not increase above 65 years of age (OR 1.02), by contrast to influenza VCR (OR 4.14) that increased significantly, suggesting that an age-based recommendation for pneumococcal vaccination will probably benefit to VCR in at-risk, elderly population.CONCLUSIONIn France, pneumococcal VCR did not increase above 65 years of age (OR 1.02), by contrast to influenza VCR (OR 4.14) that increased significantly, suggesting that an age-based recommendation for pneumococcal vaccination will probably benefit to VCR in at-risk, elderly population. |
| Audience | Academic |
| Author | Wyplosz, Benjamin Fernandes, Jérôme Fougère, Bertrand Grenier, Benjamin Goussiaume, Gwenael Loubet, Paul Blanc, Emmanuelle Roche, Nicolas Raguideau, Fanny Duhot, Didier Moulin, Bruno Sultan, Ariane Roubille, François |
| AuthorAffiliation | 5 Virulence Bactérienne et Infections Chroniques, INSERM U1047, University Montpellier, Service des Maladies Infectieuses et Tropicales, CHU Nîmes, Nîmes, France 7 Division of Geriatric Medicine, Tours University Hospital, Tours, France 6 PhyMedExp, University Montpellier, CNRS, INSERM, Endocrinology-Diabetology-Nutrition Department, University Montpellier, Montpellier, France George Washington University School of Medicine and Health Sciences, UNITED STATES OF AMERICA 1 AP-HP, Hospitalisation à Domicile, Département Adulte, Institut Pasteur, Centre Médical, Paris, France 4 PhyMedExp, University Montpellier, CNRS, INSERM, Cardiology, Montpellier University Hospital, Montpellier, France 2 Epidemiology Department, Heva, Lyon, France 10 Société Française de Médecine Générale, Issy les Moulineaux, France 8 EA 7505 Education, Ethics, Health, Tours University, Tours, France 9 Medical Information Department, Bayonne Hospital, Bayonne, France 12 Pfizer Vaccines, Paris, France 3 AP-HP, Pneumology, Cochin |
| AuthorAffiliation_xml | – name: 5 Virulence Bactérienne et Infections Chroniques, INSERM U1047, University Montpellier, Service des Maladies Infectieuses et Tropicales, CHU Nîmes, Nîmes, France – name: 3 AP-HP, Pneumology, Cochin Hospital, Paris, France – name: 10 Société Française de Médecine Générale, Issy les Moulineaux, France – name: 8 EA 7505 Education, Ethics, Health, Tours University, Tours, France – name: 11 Nephrology and Transplantation, Strasbourg University Hospital, Strasbourg, France – name: 1 AP-HP, Hospitalisation à Domicile, Département Adulte, Institut Pasteur, Centre Médical, Paris, France – name: 9 Medical Information Department, Bayonne Hospital, Bayonne, France – name: 7 Division of Geriatric Medicine, Tours University Hospital, Tours, France – name: 6 PhyMedExp, University Montpellier, CNRS, INSERM, Endocrinology-Diabetology-Nutrition Department, University Montpellier, Montpellier, France – name: 12 Pfizer Vaccines, Paris, France – name: 4 PhyMedExp, University Montpellier, CNRS, INSERM, Cardiology, Montpellier University Hospital, Montpellier, France – name: 2 Epidemiology Department, Heva, Lyon, France – name: George Washington University School of Medicine and Health Sciences, UNITED STATES OF AMERICA |
| Author_xml | – sequence: 1 givenname: Benjamin surname: Wyplosz fullname: Wyplosz, Benjamin – sequence: 2 givenname: Benjamin orcidid: 0000-0002-2373-1872 surname: Grenier fullname: Grenier, Benjamin – sequence: 3 givenname: Nicolas surname: Roche fullname: Roche, Nicolas – sequence: 4 givenname: François surname: Roubille fullname: Roubille, François – sequence: 5 givenname: Paul surname: Loubet fullname: Loubet, Paul – sequence: 6 givenname: Ariane surname: Sultan fullname: Sultan, Ariane – sequence: 7 givenname: Bertrand surname: Fougère fullname: Fougère, Bertrand – sequence: 8 givenname: Jérôme surname: Fernandes fullname: Fernandes, Jérôme – sequence: 9 givenname: Didier surname: Duhot fullname: Duhot, Didier – sequence: 10 givenname: Bruno surname: Moulin fullname: Moulin, Bruno – sequence: 11 givenname: Fanny surname: Raguideau fullname: Raguideau, Fanny – sequence: 12 givenname: Emmanuelle surname: Blanc fullname: Blanc, Emmanuelle – sequence: 13 givenname: Gwenael surname: Goussiaume fullname: Goussiaume, Gwenael |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/40788911$$D View this record in MEDLINE/PubMed https://hal.science/hal-05207470$$DView record in HAL |
| BookMark | eNqNk1tv0zAUxyM0xC7wDRBEQkLsIcWXxHF5QdXEWKVKQ9xeLcc5aT1SO9hORR_55jhrNzXTHlAeEh3__v9zic9pcmSsgSR5idEE0xK_v7G9M7KddDE8QZRMS0SfJCd4SknGCKJHB9_Hyan3NwgVlDP2LDnOUcn5FOOT5O8XA_3aKquUbNONVEobGbQ1qQwpK9ItSOdTaerRmbIbcHIJqR64zGn_K5V13wb_IZ2lDoKzvgMV9AbSznZ9eyvLKumhTn3o6-2gvHTSKHiePG1k6-HF_n2W_Lj89P3iKltcf55fzBaZYiUPWYMUBVZSRKdAGWqAKE54hbmSvMgZhRpRTlGZFxUDziiWiE-jIOekyhEwepa83vl2rfViPz0vKIkzKQjneSTmO6K28kZ0Tq-l2wortbgNWLcU0gWtWhBVFKFcKcXrmIGzSlUsV6iJpUpVV4PXx322vlpDrcAEJ9uR6fjE6JVY2o3AhFLOMYoO5zuH1QPd1WwhhhgqSGy3RBsS2Xf7bM7-7sEHsdZeQdtKA7bfNVnikrKhsDcP0MdHsaeWMnarTWNjkWowFTNeYEIKhIYSJ49Q8alhrVW8l42O8ZHgfCSITIA_YSl778X829f_Z69_jtm3B-wKZBtW3rb9cOv8GHx1-Fvu53q3EBHId4CKV9g7aO4RjMSwd3fjEsPeif3e0X9m1x2m |
| Cites_doi | 10.4300/JGME-D-12-00156.1 10.1016/j.revmed.2014.11.009 10.1016/S1473-3099(24)00665-0 10.1097/MLR.0000000000001745 10.1016/j.acap.2021.01.017 10.1093/ofid/ofad192 10.1016/j.rmra.2020.08.002 10.1016/j.rmed.2018.02.007 10.1007/s10096-019-03485-3 10.15585/mmwr.mm7104a1 10.1093/ofid/ofae349 10.1002/pds.4233 10.1016/j.vaccine.2022.06.071 10.1001/jama.2024.21060 10.1016/j.idnow.2021.07.006 10.15585/mmwr.rr7203a1 10.1016/j.vaccine.2021.04.013 10.1016/j.amepre.2017.01.014 10.1086/313792 10.1016/S1473-3099(20)30165-1 10.1016/j.rmra.2020.08.004 10.1016/j.respe.2010.04.005 |
| ContentType | Journal Article |
| Copyright | Copyright: © 2025 Wyplosz et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. COPYRIGHT 2025 Public Library of Science 2025 Wyplosz et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. Attribution 2025 Wyplosz et al 2025 Wyplosz et al 2025 Wyplosz et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: Copyright: © 2025 Wyplosz et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. – notice: COPYRIGHT 2025 Public Library of Science – notice: 2025 Wyplosz et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: Attribution – notice: 2025 Wyplosz et al 2025 Wyplosz et al – notice: 2025 Wyplosz et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM IOV ISR 3V. 7QG 7QL 7QO 7RV 7SN 7SS 7T5 7TG 7TM 7U9 7X2 7X7 7XB 88E 8AO 8C1 8FD 8FE 8FG 8FH 8FI 8FJ 8FK ABJCF ABUWG AEUYN AFKRA ARAPS ATCPS AZQEC BBNVY BENPR BGLVJ BHPHI C1K CCPQU D1I DWQXO FR3 FYUFA GHDGH GNUQQ H94 HCIFZ K9. KB. KB0 KL. L6V LK8 M0K M0S M1P M7N M7P M7S NAPCQ P5Z P62 P64 PATMY PDBOC PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PTHSS PYCSY RC3 7X8 1XC VOOES 5PM DOA |
| DOI | 10.1371/journal.pone.0329703 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Gale In Context: Opposing Viewpoints Gale In Context: Science ProQuest Central (Corporate) Animal Behavior Abstracts Bacteriology Abstracts (Microbiology B) Biotechnology Research Abstracts Nursing & Allied Health Database Ecology Abstracts Entomology Abstracts (Full archive) Immunology Abstracts Meteorological & Geoastrophysical Abstracts Nucleic Acids Abstracts Virology and AIDS Abstracts Agricultural Science Collection Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database Technology Research Database ProQuest SciTech Collection ProQuest Technology Collection ProQuest Natural Science Collection ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) Materials Science & Engineering Collection ProQuest Central (Alumni) ProQuest One Sustainability ProQuest Central UK/Ireland Advanced Technologies & Computer Science Collection Agricultural & Environmental Science Collection ProQuest Central Essentials - QC Biological Science Collection ProQuest Central Technology Collection (via ProQuest SciTech Premium Collection) Natural Science Collection Environmental Sciences and Pollution Management ProQuest One ProQuest Materials Science Collection ProQuest Central Engineering Research Database Proquest Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student AIDS and Cancer Research Abstracts SciTech Premium Collection (via ProQuest) ProQuest Health & Medical Complete (Alumni) Materials Science Database Nursing & Allied Health Database (Alumni Edition) Meteorological & Geoastrophysical Abstracts - Academic ProQuest Engineering Collection Biological Sciences Agricultural Science Database ProQuest Health & Medical Collection Medical Database Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Database Engineering Database Nursing & Allied Health Premium Advanced Technologies & Aerospace Database ProQuest Advanced Technologies & Aerospace Collection Biotechnology and BioEngineering Abstracts Environmental Science Database Materials Science Collection ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic (retired) ProQuest One Academic UKI Edition Engineering Collection Environmental Science Collection Genetics Abstracts MEDLINE - Academic Hyper Article en Ligne (HAL) Hyper Article en Ligne (HAL) (Open Access) PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Agricultural Science Database Publicly Available Content Database ProQuest Central Student ProQuest Advanced Technologies & Aerospace Collection ProQuest Central Essentials Nucleic Acids Abstracts SciTech Premium Collection Environmental Sciences and Pollution Management ProQuest One Applied & Life Sciences ProQuest One Sustainability Health Research Premium Collection Meteorological & Geoastrophysical Abstracts Natural Science Collection Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) Engineering Collection Advanced Technologies & Aerospace Collection Engineering Database Virology and AIDS Abstracts ProQuest Biological Science Collection ProQuest One Academic Eastern Edition Agricultural Science Collection ProQuest Hospital Collection ProQuest Technology Collection Health Research Premium Collection (Alumni) Biological Science Database Ecology Abstracts ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts Environmental Science Collection Entomology Abstracts Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest One Academic UKI Edition Environmental Science Database ProQuest Nursing & Allied Health Source (Alumni) Engineering Research Database ProQuest One Academic Meteorological & Geoastrophysical Abstracts - Academic ProQuest One Academic (New) Technology Collection Technology Research Database ProQuest One Academic Middle East (New) Materials Science Collection ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Central ProQuest Health & Medical Research Collection Genetics Abstracts ProQuest Engineering Collection Biotechnology Research Abstracts Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) Agricultural & Environmental Science Collection AIDS and Cancer Research Abstracts Materials Science Database ProQuest Materials Science Collection ProQuest Public Health ProQuest Nursing & Allied Health Source ProQuest SciTech Collection Advanced Technologies & Aerospace Database ProQuest Medical Library Animal Behavior Abstracts Materials Science & Engineering Collection Immunology Abstracts ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Agricultural Science Database MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: PIMPY name: ProQuest Publicly Available Content Database url: http://search.proquest.com/publiccontent sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Sciences (General) |
| DocumentTitleAlternate | Pneumococcal vaccination at 65 years |
| EISSN | 1932-6203 |
| ExternalDocumentID | 3238652884 oai_doaj_org_article_b38604ccc8d74886bcb64c0f678acdb4 PMC12338810 oai:HAL:hal-05207470v2 A851225000 40788911 10_1371_journal_pone_0329703 |
| Genre | Journal Article |
| GeographicLocations | France |
| GeographicLocations_xml | – name: France |
| GrantInformation_xml | – fundername: ; |
| GroupedDBID | --- 123 29O 2WC 53G 5VS 7RV 7X2 7X7 7XC 88E 8AO 8C1 8CJ 8FE 8FG 8FH 8FI 8FJ A8Z AAFWJ AAUCC AAWOE AAYXX ABDBF ABIVO ABJCF ABUWG ACCTH ACGFO ACIHN ACIWK ACPRK ACUHS ADBBV AEAQA AENEX AEUYN AFFHD AFKRA AFPKN AFRAH AHMBA ALMA_UNASSIGNED_HOLDINGS AOIJS APEBS ARAPS ATCPS BAIFH BAWUL BBNVY BBTPI BCNDV BENPR BGLVJ BHPHI BKEYQ BPHCQ BVXVI BWKFM CCPQU CITATION CS3 D1I D1J D1K DIK DU5 E3Z EAP EAS EBD EMOBN ESX EX3 F5P FPL FYUFA GROUPED_DOAJ GX1 HCIFZ HH5 HMCUK HYE IAO IEA IGS IHR IHW INH INR IOV IPY ISE ISR ITC K6- KB. KQ8 L6V LK5 LK8 M0K M1P M48 M7P M7R M7S M~E NAPCQ O5R O5S OK1 OVT P2P P62 PATMY PDBOC PHGZM PHGZT PIMPY PJZUB PPXIY PQGLB PQQKQ PROAC PSQYO PTHSS PV9 PYCSY RNS RPM RZL SV3 TR2 UKHRP WOQ WOW ~02 ~KM ADRAZ ALIPV CGR CUY CVF ECM EIF IPNFZ NPM RIG PUEGO 3V. 7QG 7QL 7QO 7SN 7SS 7T5 7TG 7TM 7U9 7XB 8FD 8FK AZQEC C1K DWQXO ESTFP FR3 GNUQQ H94 K9. KL. M7N P64 PKEHL PQEST PQUKI RC3 7X8 1XC VOOES 5PM |
| ID | FETCH-LOGICAL-c678t-f0c3e673039e360fe2c828b18ca85463ed03830745b6e8631a089e67482b40e63 |
| IEDL.DBID | M7P |
| ISICitedReferencesCount | 0 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001548327600048&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1932-6203 |
| IngestDate | Wed Nov 12 00:00:42 EST 2025 Tue Oct 14 19:08:48 EDT 2025 Tue Nov 04 02:05:06 EST 2025 Thu Oct 30 06:51:13 EDT 2025 Mon Sep 08 05:45:50 EDT 2025 Tue Oct 07 07:48:07 EDT 2025 Sat Nov 29 13:45:44 EST 2025 Sat Nov 29 10:30:48 EST 2025 Wed Nov 26 10:43:24 EST 2025 Wed Nov 26 10:43:16 EST 2025 Tue Aug 26 02:12:33 EDT 2025 Fri Aug 15 02:01:22 EDT 2025 Sat Nov 29 07:39:49 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 8 |
| Language | English |
| License | Copyright: © 2025 Wyplosz et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Attribution: http://creativecommons.org/licenses/by This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Creative Commons Attribution License |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c678t-f0c3e673039e360fe2c828b18ca85463ed03830745b6e8631a089e67482b40e63 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 Competing Interests: I have read the journal's policy and the authors of this manuscript have the following competing interests: BW received Payments from for lectures from Pfizer, Sanofi, Lilly, GSK, for meetings from Pfizer. BG and FR are employees of Heva, the CRO which received payments from Pfizer to conduct the study. NR received institutional grants, consulting fees, honoraria for lectures from Chiesi, GSK, Pfizer, consulting fees and honoraria for lectures from AstraZeneca, Sanofi, Teva, consulting fees from Austral and Biosency, honoraria for lectures, from Zambon, MSD, Menarini and support for meetings from Chiesi, AstraZeneca, GSK. FRoub received honoraria for lectures from Astra Zeneca, Servier, Boehringer, Astra Zeneca, Vifor, Bayer, Pfizer, Novartis, Servier, Novonordisk, Air liquid, Abbott, QuidelOrtho, Newcard, MSD, BMS, Sanofi, Alnylam, Zoll, Implicity, GSK, BMS, consulting fees from Abbott, Air liquide Bayer, Pfizer, support for travel from Novartis, Boehringer-Ingelheim, participates in an advisory board for Carmat, fiduciary role for Boehringer-Ingelheim, Vifor Pharma, Novartis, medical writting from Pfizer. PL received consulting fees from Pfizer, GSK, Sanofi, honoraria for lecture from Pfizer, GSK, Sanofi, Moderna, MSD, Support for attending meeting from Pfizer, Astrazeneca, MSD, Sanofi, GSK. AS received Grants from VIATRIS, SERVIER, Consulting fees from PFIZER, SANOFI, LILLY, SERVIER, ASTRA, DEBEX, NOVARTIS, URGO, honoraria for lectures from PFIZER, SANOFI, LILLY, SERVIER, ASTRA, DEBEX, NOVARTIS, ABOTT, MSD. BF received Consulting fees from Sanofi, AstraZeneca, Pfizer, GSK, honoraria for lectures from Sanofi, AstraZeneca, Pfizer, GSK, CSL Seqirus, Participation on a Data Safety Monitoring Board or Advisory Board for Pfizer. JF received Grants from Astra ZENECA ASTELLAS Pharma ABBVIE JANSSEN BMS, Consulting fees from Astra ZENECA ASTELLAS Pharma ABBVIE JANSSEN BMS, honoraria for lectures from Astra ZENECA ASTELLAS Pharma ABBVIE JANSSEN BMS. DD received honoraria for lecture from Pfizer, BM received honoraria for lecture from Pfizer. EB and GG are employees from Pfizer and may hold stock options. This does not alter our adherence to PLOS ONE policies on sharing data and materials. |
| ORCID | 0000-0002-2373-1872 0000-0002-5288-9687 0000-0002-4809-3547 |
| OpenAccessLink | https://www.proquest.com/docview/3238652884?pq-origsite=%requestingapplication% |
| PMID | 40788911 |
| PQID | 3238652884 |
| PQPubID | 1436336 |
| PageCount | e0329703 |
| ParticipantIDs | plos_journals_3238652884 doaj_primary_oai_doaj_org_article_b38604ccc8d74886bcb64c0f678acdb4 pubmedcentral_primary_oai_pubmedcentral_nih_gov_12338810 hal_primary_oai_HAL_hal_05207470v2 proquest_miscellaneous_3238717364 proquest_journals_3238652884 gale_infotracmisc_A851225000 gale_infotracacademiconefile_A851225000 gale_incontextgauss_ISR_A851225000 gale_incontextgauss_IOV_A851225000 gale_healthsolutions_A851225000 pubmed_primary_40788911 crossref_primary_10_1371_journal_pone_0329703 |
| PublicationCentury | 2000 |
| PublicationDate | 2025-08-11 |
| PublicationDateYYYYMMDD | 2025-08-11 |
| PublicationDate_xml | – month: 08 year: 2025 text: 2025-08-11 day: 11 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: San Francisco – name: San Francisco, CA USA |
| PublicationTitle | PloS one |
| PublicationTitleAlternate | PLoS One |
| PublicationYear | 2025 |
| Publisher | Public Library of Science Public Library of Science (PLoS) |
| Publisher_xml | – name: Public Library of Science – name: Public Library of Science (PLoS) |
| References | A Rachas (pone.0329703.ref024) 2022; 60 ND Johansen (pone.0329703.ref039) 2024; 332 A Sabra (pone.0329703.ref004) 2024; 11 HAS Haute Autorité deSanté (pone.0329703.ref035) 2022 TT Yoshikawa (pone.0329703.ref001) 2000; 30 A Torres (pone.0329703.ref002) 2018; 137 M Kobayashi (pone.0329703.ref037) 2022; 71 E Varon (pone.0329703.ref022) 2020; 12 SPBS York (pone.0329703.ref031) 2022 B Wyplosz (pone.0329703.ref014) 2022; 40 S Bouée (pone.0329703.ref025) 2018; 66 GM Sullivan (pone.0329703.ref029) 2012; 4 pone.0329703.ref008 P Tuppin (pone.0329703.ref019) 2010; 58 N Jourde-Chiche (pone.0329703.ref026) 2023; 18 pone.0329703.ref028 N Ouldali (pone.0329703.ref005) 2021; 21 C Bonnave (pone.0329703.ref009) 2019; 38 A Kini (pone.0329703.ref030) 2022; 40 G Bernède (pone.0329703.ref027) 2023; 18 P Tuppin (pone.0329703.ref020) 2017 J Bezin (pone.0329703.ref017) 2017; 26 M Kobayashi (pone.0329703.ref038) 2023; 72 JC Bennett (pone.0329703.ref006) 2025; 25 NT Brewer (pone.0329703.ref011) 2021; 21 G Moulis (pone.0329703.ref018) 2015; 36 E Blanchard (pone.0329703.ref023) 2020; 12 S Kernéis (pone.0329703.ref034) 2017; 53 pone.0329703.ref016 pone.0329703.ref036 pone.0329703.ref015 pone.0329703.ref012 pone.0329703.ref013 HAS Haute Autorité de Santé (pone.0329703.ref007) 2023 pone.0329703.ref010 pone.0329703.ref032 pone.0329703.ref033 B Wyplosz (pone.0329703.ref021) 2021; 51 LR Grant (pone.0329703.ref003) 2023; 10 |
| References_xml | – volume: 4 start-page: 279 issue: 3 year: 2012 ident: pone.0329703.ref029 article-title: Using Effect Size-or Why the P Value Is Not Enough publication-title: J Grad Med Educ doi: 10.4300/JGME-D-12-00156.1 – ident: pone.0329703.ref015 – volume: 36 start-page: 411 issue: 6 year: 2015 ident: pone.0329703.ref018 article-title: French health insurance databases: What interest for medical research? publication-title: Rev Med Interne doi: 10.1016/j.revmed.2014.11.009 – volume: 66 year: 2018 ident: pone.0329703.ref025 article-title: Identification et estimation de la prévalence de l’asthme sévère en France via l’échantillon généraliste de bénéficiaires publication-title: Revue d’Épidémiologie et de Santé Publique – volume: 25 start-page: 457 issue: 4 year: 2025 ident: pone.0329703.ref006 article-title: Global impact of ten-valent and 13-valent pneumococcal conjugate vaccines on invasive pneumococcal disease in all ages (the PSERENADE project): a global surveillance analysis publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(24)00665-0 – volume: 60 start-page: 655 issue: 9 year: 2022 ident: pone.0329703.ref024 article-title: The Economic Burden of Disease in France From the National Health Insurance Perspective: The Healthcare Expenditures and Conditions Mapping Used to Prepare the French Social Security Funding Act and the Public Health Act publication-title: Med Care doi: 10.1097/MLR.0000000000001745 – volume: 21 year: 2021 ident: pone.0329703.ref011 article-title: What Works to Increase Vaccination Uptake publication-title: Acad Pediatr doi: 10.1016/j.acap.2021.01.017 – volume: 10 issue: 5 year: 2023 ident: pone.0329703.ref003 article-title: Risk of Pneumococcal Disease in US Adults by Age and Risk Profile publication-title: Open Forum Infect Dis doi: 10.1093/ofid/ofad192 – volume: 12 year: 2020 ident: pone.0329703.ref023 article-title: Guide pratique de vaccination en pneumologie publication-title: Revue des Maladies Respiratoires Actualités doi: 10.1016/j.rmra.2020.08.002 – ident: pone.0329703.ref036 – start-page: 14 volume-title: Patterns in Pneumococcal Vaccination Among Adults year: 2022 ident: pone.0329703.ref031 – volume: 137 start-page: 6 year: 2018 ident: pone.0329703.ref002 article-title: Burden of pneumococcal community-acquired pneumonia in adults across Europe: A literature review publication-title: Respir Med doi: 10.1016/j.rmed.2018.02.007 – volume: 38 start-page: 785 issue: 4 year: 2019 ident: pone.0329703.ref009 article-title: Adult vaccination for pneumococcal disease: a comparison of the national guidelines in Europe publication-title: Eur J Clin Microbiol Infect Dis doi: 10.1007/s10096-019-03485-3 – ident: pone.0329703.ref028 – year: 2017 ident: pone.0329703.ref020 article-title: Value of a national administrative database to guide public decisions: From the système national d’information interrégimes de l’Assurance Maladie (SNIIRAM) to the système national des données de santé (SNDS) in France publication-title: Rev Epidemiol Sante Publique – ident: pone.0329703.ref033 – volume: 71 start-page: 109 issue: 4 year: 2022 ident: pone.0329703.ref037 article-title: Use of 15-Valent Pneumococcal Conjugate Vaccine and 20-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, 2022 publication-title: MMWR Morb Mortal Wkly Rep doi: 10.15585/mmwr.mm7104a1 – ident: pone.0329703.ref012 – volume: 11 issue: 7 year: 2024 ident: pone.0329703.ref004 article-title: Hospital Burden of All-Cause Pneumonia and Nonbacteremic Pneumococcal Pneumonia in Adults in France Between 2013 and 2019 publication-title: Open Forum Infect Dis doi: 10.1093/ofid/ofae349 – ident: pone.0329703.ref010 – volume: 26 start-page: 954 issue: 8 year: 2017 ident: pone.0329703.ref017 article-title: The national healthcare system claims databases in France, SNIIRAM and EGB: Powerful tools for pharmacoepidemiology publication-title: Pharmacoepidemiol Drug Saf doi: 10.1002/pds.4233 – volume: 40 start-page: 4911 issue: 33 year: 2022 ident: pone.0329703.ref014 article-title: Pneumococcal and influenza vaccination coverage among at-risk adults: A 5-year French national observational study publication-title: Vaccine doi: 10.1016/j.vaccine.2022.06.071 – volume-title: Élargissement des compétences en matière de vaccination des infirmiers, des pharmaciens et des sages-femmes chez les adolescents de plus de 16 ans et les adultes year: 2022 ident: pone.0329703.ref035 – ident: pone.0329703.ref016 – volume: 332 start-page: 1900 issue: 22 year: 2024 ident: pone.0329703.ref039 article-title: Electronic Nudges to Increase Influenza Vaccination in Patients With Chronic Diseases: A Randomized Clinical Trial publication-title: JAMA doi: 10.1001/jama.2024.21060 – volume: 51 start-page: 661 issue: 8 year: 2021 ident: pone.0329703.ref021 article-title: Adults at risk of pneumococcal disease in France publication-title: Infect Dis Now doi: 10.1016/j.idnow.2021.07.006 – volume: 18 start-page: 94 year: 2023 ident: pone.0329703.ref027 article-title: The information system of REIN publication-title: Nephrol Ther – volume: 72 start-page: 1 issue: 3 year: 2023 ident: pone.0329703.ref038 article-title: Pneumococcal Vaccine for Adults Aged ≥19 Years: Recommendations of the Advisory Committee on Immunization Practices, United States, 2023 publication-title: MMWR Recomm Rep doi: 10.15585/mmwr.rr7203a1 – volume: 40 start-page: 1643 issue: 11 year: 2022 ident: pone.0329703.ref030 article-title: Differences and disparities in seasonal influenza vaccine, acceptance, adverse reactions, and coverage by age, sex, gender, and race publication-title: Vaccine doi: 10.1016/j.vaccine.2021.04.013 – volume: 18 start-page: 70 year: 2023 ident: pone.0329703.ref026 article-title: REIN: a tool to support scientific research publication-title: Nephrol Ther – volume-title: Stratégie de vaccination contre les infections à pneumocoque - Place du vaccin pneumococcique polyosidique conjugué (20-valent, adsorbé) chez l’adulte year: 2023 ident: pone.0329703.ref007 – volume: 53 issue: 3 year: 2017 ident: pone.0329703.ref034 article-title: Vaccine Education of Medical Students: A Nationwide Cross-sectional Survey publication-title: Am J Prev Med doi: 10.1016/j.amepre.2017.01.014 – volume: 30 start-page: 931 issue: 6 year: 2000 ident: pone.0329703.ref001 article-title: Epidemiology and unique aspects of aging and infectious diseases publication-title: Clin Infect Dis doi: 10.1086/313792 – volume: 21 start-page: 137 issue: 1 year: 2021 ident: pone.0329703.ref005 article-title: Invasive pneumococcal disease incidence in children and adults in France during the pneumococcal conjugate vaccine era: an interrupted time-series analysis of data from a 17-year national prospective surveillance study publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(20)30165-1 – ident: pone.0329703.ref032 – ident: pone.0329703.ref008 – ident: pone.0329703.ref013 – volume: 12 year: 2020 ident: pone.0329703.ref022 article-title: Pneumocoque publication-title: Revue des Maladies Respiratoires Actualités doi: 10.1016/j.rmra.2020.08.004 – volume: 58 start-page: 286 issue: 4 year: 2010 ident: pone.0329703.ref019 article-title: French national health insurance information system and the permanent beneficiaries sample publication-title: Rev Epidemiol Sante Publique doi: 10.1016/j.respe.2010.04.005 |
| SSID | ssj0053866 |
| Score | 2.4849005 |
| Snippet | Age (> 50 years) is a risk factor for pneumococcal disease, but is not an indication for vaccination in France, by contrast to influenza. In 2018, the... Objectives Age (> 50 years) is a risk factor for pneumococcal disease, but is not an indication for vaccination in France, by contrast to influenza. In 2018,... ObjectivesAge (> 50 years) is a risk factor for pneumococcal disease, but is not an indication for vaccination in France, by contrast to influenza. In 2018,... Objectives: Age (> 50 years) is a risk factor for pneumococcal disease, but is not an indication for vaccination in France, by contrast to influenza. In 2018,... Objectives Age (> 50 years) is a risk factor for pneumococcal disease, but is not an indication for vaccination in France, by contrast to influenza. In 2018,... |
| SourceID | plos doaj pubmedcentral hal proquest gale pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database |
| StartPage | e0329703 |
| SubjectTerms | Adult Adults Age Aged Aged, 80 and over Algorithms Asthma Biology and Life Sciences Chronic illnesses Chronic obstructive pulmonary disease Cochlear implants Comorbidity Demographic aspects Diabetes Dosage and administration Drug dosages Female France - epidemiology Geriatry and gerontology Health aspects HIV Human health and pathology Human immunodeficiency virus Humans Immunology Infectious diseases Influenza Influenza Vaccines Influenza, Human - epidemiology Influenza, Human - prevention & control Kidney diseases Life Sciences Liver diseases Lung diseases Male Medicine and Health Sciences Middle Aged Patients People and places Pneumococcal infections Pneumococcal Infections - epidemiology Pneumococcal Infections - prevention & control Pneumococcal vaccine Pneumococcal Vaccines - administration & dosage Pneumococcal Vaccines - therapeutic use Pneumonia Polysaccharides Population Population studies Prevention Pulmonology and respiratory tract Retrospective Studies Risk Factors Santé publique et épidémiologie Schedules Transplants & implants Vaccination - statistics & numerical data Vaccination Coverage - statistics & numerical data Vaccines Vaccinology Young Adult |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lj9MwELag4sAFsbw2UMAgJOCQ3SRuHZdbQawWCS0rXtqbZU8cWgmSqmkrceSfM-M4UYNWggPXeKLE8_JMMvMNY88kmKlTkMZ5WmKCYp2Ibemy2KYYrjvCO4HCD5vIz87UxcXsfG_UF9WEtfDALeOOrVAymQCAKvBGJS1YOYGkRCdroLAeCRSjni6Zan0wWrGUoVFO5OlxkMvRqq7cUSKyWd4NyQoHkcfr773y1QUVRY5W3-vmssDzz_rJvQPp5Ca7ESJJPm93cMCuuOoWOwi22vAXAVD65W3267xy2x81uj4UCN8ZgGX7DZCbDZdT_hO1veGmKgZrQMWd6G34kuhiqkHnHq2jecXnfO0267pr0-SrfgxYTMdiwT1qLd3pB3e4O-zLydvPb07jMHohBmTsJi4TEE6i9YuZEzJB6QGmZjZVYBQB6LsiwdQWw4-plU5JkZpEzRwNLsnsJHFS3GWjCpl9yHhhM1cWqswLg7m4lIZ6V2emcNnUQQ5pxOJODnrVImxo_5stx8ykZaUmuekgt4i9JmH1tISP7S-g1uigNfpvWhOxxyRq3Tab9lau5xiAoofDcyJiTz0FYWRUVITzzWybRr_78PUfiD59HBA9D0RljeoCJjQ-4J4Ie2tAOR5QoqXD8GkLYsbexk_n7zVdo2omTAyTXRaxQ9LbjnWNFhmNdc2Uwk2PO12-fPlJv0xPpuq7ytXbloaqNSTS3GtVv38L-g-s8MSMmBoYxeA1hyvVcuFxzDFoEkqlyf3_IdEH7HpGo5kJrTgds9FmvXUP2TXYbZbN-pH3Dr8Bbwlqnw priority: 102 providerName: Directory of Open Access Journals – databaseName: Public Library of Science (PLoS) Journals Open Access dbid: FPL link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lj9MwELagcOACLI_dQAGDkIBDliRuHYdbQVSLtFoqXtqbZU8cWgmSqkkrceSfM5MXm9WuBNd4otjjecbjbxh7LsFMnYLQj8MMExTrhG8zF_k2xHDdEd4JpHWzifjkRJ2eJou_ieK5E3wRh69bnh6ui9wdBiJKYgL3vBYJKamEa7447iwv6q6U7fW4y94cuJ8apb-3xVeXVAo5Wv8oyovCzfNVk2fc0PzW_y7gNrvZBpx81kjIHrvi8jtsr1Xpkr9scadf3WW_F7nb_izQQuK-8Z0BWDW_CrmpuJzyX6gUJTd5OhgDqgFFo8RXROdTqTqvQT3KN3zGN67aFN1tTr7uu4X55D1TXoPb0pt1fw93j32dv__y7shvOzT4gE6u8rMAhJNoJETihAxwkwEzOBsqMIpw9l0aYAaMUcrUSqekCE2gEkf9TSI7CZwU99koR7YcMJ7ayGWpyuLUYMoupaErrolJXTR1EEPoMb_bOL1ugDh0fRoXYwLTsFITh3XLYY-9pd3taQlGu36AW6NbrdQWJSaYAIBKcU5KWrByAkGGizOQ2onHnpBs6OZOam8M9AzjVDSE6E489qymICiNnGp1vpttWeoPH7_9A9HnTwOiFy1RVqB8gWnvR-CaCKJrQDkeUKJBgOHXlsSMMws_mh1rekZFT5g_BrvIYwck6B3rSi0i6v4aKYWLHnfCf_Hw036YvkxFerkrtg0NFXVIpNlvdKWfBR0XK3SsHlMDLRpMcziSr5Y13DnGVkKpMHhw-ZQfshsR9WUmqOJwzEbVZuseseuwq1bl5nFtJP4A6wBmJw priority: 102 providerName: Public Library of Science |
| Title | Pneumococcal vaccination at 65 years and vaccination coverage in at-risk adults: A retrospective population-based study in France |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/40788911 https://www.proquest.com/docview/3238652884 https://www.proquest.com/docview/3238717364 https://hal.science/hal-05207470 https://pubmed.ncbi.nlm.nih.gov/PMC12338810 https://doaj.org/article/b38604ccc8d74886bcb64c0f678acdb4 http://dx.doi.org/10.1371/journal.pone.0329703 |
| Volume | 20 |
| WOSCitedRecordID | wos001548327600048&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: DOA dateStart: 20060101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: M~E dateStart: 20060101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVPQU databaseName: Advanced Technologies & Aerospace Database customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: P5Z dateStart: 20061201 isFulltext: true titleUrlDefault: https://search.proquest.com/hightechjournals providerName: ProQuest – providerCode: PRVPQU databaseName: Agricultural Science Database customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: M0K dateStart: 20061201 isFulltext: true titleUrlDefault: https://search.proquest.com/agriculturejournals providerName: ProQuest – providerCode: PRVPQU databaseName: Biological Science Database customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: M7P dateStart: 20061201 isFulltext: true titleUrlDefault: http://search.proquest.com/biologicalscijournals providerName: ProQuest – providerCode: PRVPQU databaseName: Engineering Database customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: M7S dateStart: 20061201 isFulltext: true titleUrlDefault: http://search.proquest.com providerName: ProQuest – providerCode: PRVPQU databaseName: Environmental Science Database customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: PATMY dateStart: 20061201 isFulltext: true titleUrlDefault: http://search.proquest.com/environmentalscience providerName: ProQuest – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: 7X7 dateStart: 20061201 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: Materials Science Database customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: KB. dateStart: 20061201 isFulltext: true titleUrlDefault: http://search.proquest.com/materialsscijournals providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: BENPR dateStart: 20061201 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Nursing and Allied Health Journals - PSU access expires 11/30/25. customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: 7RV dateStart: 20061201 isFulltext: true titleUrlDefault: https://search.proquest.com/nahs providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Publicly Available Content Database customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: PIMPY dateStart: 20061201 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest – providerCode: PRVPQU databaseName: Public Health Database customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: 8C1 dateStart: 20061201 isFulltext: true titleUrlDefault: https://search.proquest.com/publichealth providerName: ProQuest – providerCode: PRVATS databaseName: Public Library of Science (PLoS) Journals Open Access customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: FPL dateStart: 20060101 isFulltext: true titleUrlDefault: http://www.plos.org/publications/ providerName: Public Library of Science |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3db9MwELdoxwMvwPhaYBSDkICHdPloHZcX1E6bNm0rUQdTx0vkOM5aCZLStJV45D_nznHCgiaExMs9xJfE9p3PZ_v8O0JeMyn6ikvXDtwUFiix8u04VZ4du-CuK8Q7kYlONhGMx3w6HYRmw60wYZWVTdSGOskl7pHv-R5mp_Q4731YfLcxaxSerpoUGi2yhSgJvg7dCytLDGOZMXNdzg_cPSOd7iLPVNfxvUFQpcoy05FG7a9tc2uGoZHtxde8uMn9_DOK8tq0dHjvfxt0n9w1Dikdlhq0TW6p7AHZNkO-oG8NLvW7h-RnmKn1txwsKMiVboSU83IrkYoVZX36AwZNQUWWNMokxoiC0aJz5LMxlJ1q0I_iPR3SpVot8-q2J13U2cRsnF0TqsFv8U2d_0M9Ip8PDz7tH9kmg4MtYRJc2akjfcXAiPgD5TMHlEDCCi92uRQccfhV4sAKGbyYfswUZ74rHD5QmP_Ei3uOYv5j0s5AWjuEJrGn0oSnQSJgSc-YwCuwA5Eor69kIF2L2JUgo0UJ1BHp07oAFjhlV0Yo-MgI3iIjlHbNizDb-kG-vIrMqI1iEJHTk1LyBOrEWSxj1pNOCo0TMol7FnmBuhKVd1ZrYxENwY8FQwnTjUVeaQ6E2sgwludKrIsiOv548Q9M55MG0xvDlOagb1KY-xPQJoTwanDuNjjBYMjm32bYGdcafjQ8jfAZBkXB-tLZeBbZQcWvuq6IfqsrfL5S6JuLX9bF-GcM4stUvi55MOiDAc-TcuzUtcDjZA4Tr0V4Y1Q1qtksyeYzDYcOvpfPues8_Xu9npE7HuZuRjhjd5e0V8u1ek5uy81qXiw7pBVMLpBOA005UL7vdsjW6GAcTjp6rwboYXgK9GTUBXrmnHS0wdH0HGjY_wJvhMdn4eUvi7mEgg |
| linkProvider | ProQuest |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Jb9NAFB61AQkuQNlqKHRAIODg1lvGEySEwlIlaghVW6rehvF43EQCO9hJUI_8IX4j740XalQhLj1w9bzYbybf2-y3EPKEKdnVXLl26CYQoETat6NEe3bkgruusd-Jis2wiXA85sfHvb0V8rOuhcG0ylonGkUdZwrfkW_7Hk6n9DgPXs--2Tg1Cr-u1iM0Sljs6tPvELIVr4bv4P996nk77w_fDuxqqoCtQDHP7cRRvmYAbL-nfeYAYwqijsjlSnLsDa9jB6I2sKzdiGnOfFc6vKdxJocXBY5mPtx3lVwCPe5iClm4f1RrftAdjFXleX7obldo2Jplqd5yfK8X1qO5KvNnpgQ0tmB1gqmYndmXrDjP3f0za_OMGdy5_r8d4A1yrXK4ab-UkDWyotObZK1SaQV9XvXdfnGL_NhL9eJrBhYCcEuXUqlp-aqUyjllXXoKzBdUpnFrTWEOLChlOkU6G1P1qWlqUrykfZrreZ7V1ax01kxLs9F7iKlp7ou_NPNN9G3y6UKO4g7ppICOdULjyNNJzJMwlk4AMaXEEt-ejLXX1SpUrkXsGjhiVjYiEeZrZAgBXHmUAoEmKqBZ5A2iq6HFNuLmQpafiEoriQgg4QRKKR4DT5xFKmKBchLYnFRxFFhkE7EpyprcRhmKPvjpYAjAnFrksaHAViIp5iqdyEVRiOHHo38gOthvET2riJIM8K1kVR8Ce8IWZS3KjRYlKETVftoED-PMxgf9kcBrmPQF8bOz9CyyjoJWH10hfosH3L4WoPOXHzXL-GRMUkx1tihpMKmFAc3dUlYbLvBzOQfHwiK8JcUtNtsr6XRi2r2Db-lz7jr3_s7XJrkyOPwwEqPhePc-uerhnGps3exukM48X-gH5LJazqdF_tAoLUo-X7SQ_wI7KdF5 |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9NAEF61ASEuQHnVUOiCQMDBjV9Zr5EQCi1Ro1YhooB6W9brdRMJ7BAnQT3yt_h1zNhrU6MKcemBq3diz26-ednzIOQJU7KnuXLt0E0hQIm1b8ep9uzYBXddY78TlZTDJsLRiB8fR-M18rOuhcG0ylonloo6yRW-I-_6Hk6n9DgPuqlJixjvDV7Pvtk4QQq_tNbjNCqIHOjT7xC-Fa-Ge_BfP_W8wdsPu_u2mTBgK1DSCzt1lK8ZgNyPtM8cYFJBBBK7XEmOfeJ14kAEB1a2FzPNme9Kh0ca53N4ceBo5sN918ml0AcUY5X6bpNeAnqEMVOq54du1yBjZ5ZnesfxvSisx3QZU1hODGjswvoE0zI7sy95cZ7r-2cG5xmTOLj-Px_mDXLNOOK0X0nOBlnT2U2yYVRdQZ-bftwvbpEf40wvv-ZgOQDPdCWVmlavUKlcUNajp8B8QWWWtNYU5saCsqZTpLMxhZ-WzU6Kl7RP53oxz-sqVzprpqjZ6FUktGz6i78s557o2-TjhRzFHdLJACmbhCaxp9OEp2EinQBiTYmlv5FMtNfTKlSuRewaRGJWNSgR5VfKEAK76igFgk4Y0FnkDSKtocX24uWFfH4ijLYSMcDDCZRSPAGeOItVzALlpLA5qZI4sMg24lRUtbqNkhR98N_BQICZtcjjkgJbjGSIrxO5LAoxfPfpH4iO3reInhmiNAesK2nqRmBP2LqsRbnVogRFqdpPm-BhnNn4fv9Q4DVMBoO42ll5FtlEoauPrhC_RQVuXwvT-cuPmmV8MiYvZjpfVjSY7MKA5m4ltw0X-Bmdg8NhEd6S6Bab7ZVsOinbwIPP6XPuOvf-ztc2uQKyLQ6Ho4P75KqH46uxo7O7RTqL-VI_IJfVajEt5g9L_UXJ54uW8V9da9nU |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Pneumococcal+vaccination+at+65+years+and+vaccination+coverage+in+at-risk+adults%3A+A+retrospective+population-based+study+in+France&rft.jtitle=PloS+one&rft.au=Wyplosz%2C+Benjamin&rft.au=Grenier%2C+Benjamin&rft.au=Roche%2C+Nicolas&rft.au=Roubille%2C+Fran%C3%A7ois&rft.date=2025-08-11&rft.pub=Public+Library+of+Science&rft.issn=1932-6203&rft.eissn=1932-6203&rft.volume=20&rft.issue=8&rft.spage=e0329703&rft_id=info:doi/10.1371%2Fjournal.pone.0329703&rft.externalDBID=IOV&rft.externalDocID=A851225000 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1932-6203&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1932-6203&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1932-6203&client=summon |